Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

NCT04601428 is registered in ClinicalTrials.gov with Koo Foundation Sun Yat-Sen Cancer Center as lead sponsor.

NCT NCT04601428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04601428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability
Lead sponsor
Koo Foundation Sun Yat-Sen Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
January 26, 2021
Completion date
April 9, 2026
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)